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Bayesian decision procedures have already been proposed for and implemented in phase 
I dose-escalation studies in healthy volunteers.  The procedures have been based on 
pharmacokinetic responses reflecting the concentration of the drug in blood plasma and 
are conducted to learn about the dose-response relationship while avoiding excessive 
concentrations.  However, in many dose-escalation studies, pharmacodynamic 
endpoints such as heart rate or blood pressure are observed, and it is these that should be 
used to control dose-escalation.  These endpoints introduce additional complexity into 
the modelling of the problem relative to pharmacokinetic responses.  Firstly, there are 
responses available following placebo administrations.  Secondly, the 
pharmacodynamic responses are related directly to measurable plasma concentrations, 
which in turn are related to dose.  Motivated by experience of data from a real study 
conducted in a conventional manner, this paper presents and evaluates a Bayesian 
procedure devised for the simultaneous monitoring of pharmacodynamic and 
pharmacokinetic responses.  Account is also taken of the incidence of adverse events.  
Following logarithmic transformations, a linear model is used to relate dose to the 
pharmacokinetic endpoint and a quadratic model to relate the latter to the 
pharmacodynamic endpoint.  A logistic model is used to relate the pharmacokinetic 





1.   Introduction 
Phase I dose-escalation studies are generally conducted in small samples of 
healthy male volunteers in order to determine safe doses for later experimentation.  The 
tolerability and safety of the experimental drug are closely monitored, with any adverse 
reactions being noted and pharmacokinetic responses such as AUC and Cmax being 
recorded.  Formal statistical designs for clinical trials in which binary adverse events are 
recorded have been studied by many authors, with the Continual Reassessment Method 
(O’Quigley, Pepe and Fisher, 1990) and its modifications being prominent in the 
literature.  Recent summaries of that methodology can be found in Rosenberger and 
Haines (2002), Chevret (2006) and Ting (2006).  Whitehead et al. (2001, 2006a) 
proposed Bayesian dose-escalation procedures for studies of pharmacokinetic responses 
from repeated dosing of healthy volunteers, Zhou et al. (2006) consider escalation based 
on bivariate data with one continuous and one binary component, and Zhou et al. (2007) 
describe a phase I study in which procedures for monitoring AUC and Cmax values and 
incidence of adverse reactions were operated simultaneously.  Piantadosi and Liu (1996) 
describe a dose-escalation procedure based on binary responses of toxicity in which 
pharmacokinetic measurements are taken into account.  Their objective was to put 
observations of toxicity into the context of drug concentration rather than just dose 
administered, and as subjects were dosed only once in their design, the information was 
used in recommending doses for future subjects.   
The methodology presented in this paper was motivated by a phase I dose-
escalation trial that had been carried out according to a conventional design to 
investigate a compound aimed at treating Attention Deficit and Hyperactivity Disorder 
(ADHD).  In addition to observing pharmacokinetic responses, investigators also 
recorded pharmacodynamic responses including pulse rate.  The reason for interest in 
pulse rate was that the compound under study shares the same mechanism of action as 
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Atomoxetine, a highly specific presynaptic inhibitor of the noradrenaline 
(norepinephrine) transporter recently approved in the US for the treatment of patients 
with attention-deficit/hyperactivity disorder (ADHD).  Adverse effects on the 
cardiovascular system, including abnormalities in heart rate, blood pressure, or cardiac 
rhythm have been associated with several noradrenergic medications. Under treatment, 
the mean heart rate and pulse rate increase as a consequence of the mechanism of action 
and its impact on the sympathetic and parasympathetic systems.  The increases in blood 
pressure and pulse tends to occur early in therapy, stabilise, and then return toward 
baseline upon drug discontinuation (Wernicke et al., 2003).  Because of the relationship 
between these effects and the mechnism of action of the drug on ADHD, elevation of 
pulse rate was used as a marker of pharmacological action. 
 
2. The motivating dataset 
The data concern two cohorts of 9 healthy male volunteers.  Doses investigated were 0, 
20, 40, 80, 120, 180 and 200 mg.  Cohort I participated in periods 1, 3 and 5 of the 
study, receiving doses 20, 80 and 180 mg in turn, while Cohort II participated in periods 
2, 4 and 6, receiving doses 40, 120 and 200 mg.   Within each period, six subjects 
received the active dose and three placebo, arranged so that each subject received two 
active doses over the course of the trial.   Several measurements during each dosing 
period: here we restrict attention to the AUC, the pulse rate and the incidence of adverse 
events.  A two week wash out interval separated consecutive dosing periods of the same 
cohort.  Carry over of the drug from one treatment period to the next was neither 
anticipated nor observed.  The study was conducted and interpreted in a conventional 
manner.  In this section a model is fitted to the data to form the basis of a Bayesian 
approach developed in Section 3.  In Section 4, illustrations of the Bayesian procedure 
are constructed by simulating realistic data from this model. 
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A model for AUC values was specified in terms of yij = log(AUCij + 1), where 
AUCij is the AUC for the i
th
 subject during the j
th
 period.  The reason for adding 1s will 
be explained later, but other than that we follow Whitehead et al. (2001) and model yij 
according to yij = βlij + si + εij, where lij = log(dij + 1) and dij is the dose administered to 
the i
th
 subject during the j
th
 period.  The random subject effect si and the residual εij are 
taken to be mutually independent normally distributed random variables with mean 0 
and respective variances τ2 and σ2.  The within subject correlation is ρ = τ2/(τ2 + σ2).  
Placebo data will not be used to fit the model, but it is constrained to pass through the 
origin since a placebo dose is certain to lead to an AUC of 0.  Figure 1 shows the 
resulting fit of this model to the study data.  Maximum likelihood estimates are βˆ  = 
1.709, 2τˆ  = 0.340 and 2σˆ = 0.0554, so that ρˆ= 0.860.   
FIGURE 1 NEAR HERE 
The pulse rate of the i
th
 subject during the j
th
 period data was summarised as mij, 
the maximum increase in pulse rate over baseline during that period.  A quadratic model 
in log(AUC + 1) was fitted to this endpoint: mij = θ0 + θ1yij + θ2yij2 + ri + δij, where the 
random subject effect ri and the residual δij are taken to be mutually independent 
normally distributed random variables with mean 0 and respective variances ζ2 and ξ2.  
The within subject correlation is η = ζ2/(ζ2 + ξ2).  The model is fitted to data from all 
dosing periods, including placebo administrations, for which yij is taken to be zero.  
Figure 2 shows the resulting fit of this model.  Maximum likelihood estimates are 0θˆ  = 
21.486, 1θˆ  = −2.169, 2θˆ  = 0.365, 
2ζˆ  = 15.631 and 2ξˆ = 181.79, so that ηˆ= 0.079.  The 
fit of the model appears to be satisfactory, with the relationship being close to horizontal 
between placebo and very low active doses, while at higher doses an increasing 
relationship is seen, as would be anticipated.   The addition of 1 to the AUC before log 
transformation allows responses to placebo to be included in the model for pulse rate 
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against AUC, and the addition of 1 to dose values constrains the linear model relating 
AUC to dose to pass through the origin.   
FIGURE 2 NEAR HERE 
While it is accepted that the quadratic model does not reflect the precise 
relationship between pulse rate and AUC, it is proposed as a useful working model. One 
desirable property is that it will result in conservatism during dose-escalation, because 
the accelerating gradient at higher AUC values will give the appearance that high doses 
are particularly unacceptable.  This would not be true, for example, of a split-line 
model. 
Rather than counting all adverse events, only “dose limiting events” (DLEs) 
featured in analyses.  These are loosely defined as events which would make 
investigators concerned about repeating that dose or administering higher doses, and 
more specifically taken to be any one of a list of events prepared before starting the 
study.  The probability of a DLE will be modelled as a logistic regression on 
log(AUC+1). Denoting the probability that the i
th
 subject suffers a DLE during the j
th
 
period by pij, the model logit(pij) = λ1 + λ2yij is fitted to data from active doses only.  
For the dataset available, maximum likelihood estimates were 1λˆ  = −4.055 and 2λˆ  = 
0.347.  The multivariate approach followed here allows us to relate the risk of a DLE to 
the amount of the drug absorbed (reflected by AUC), rather than the amount 
administered (reflected by dose).  The former is thus closer to the underlying 
physiological mechanism, and makes some indirect allowance for the dependence of 
repeated observations on a subject.  
The three models together describe the multivariate behaviour of AUC, pulse 
rate and DLE observations.  It is being assumed that the occurrence of a DLE is 
conditionally independent of the pulse rate observation, given the AUC value. This is 
reasonable for the adverse events considered here, which took the form of vomiting, 
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headaches, urinary hesitation and dizziness. Conditions connected with heart rate, such 
as tachycardia, would not be accommodated in such a model. Tachycardia was on the 
list of events, but occurred only once during the course of the trial.  
 
3. Bayesian modelling 
For Bayesian modelling of the AUC data, a normal-gamma prior distribution is used for 
the parameters β and σ2: βσ2 ~ N(µA0, σ2QA0−1); σ−2 ~ Ga(aA0, bA0), while a fixed 
value is set for ρ.   A similar prior is imposed on the pulse rate data: θξ2 ~ N(µP0, 
ξ2QP0−1); ξ−2 ~ Ga(aP0, bP0), with a fixed value set for η.  The posterior distributions 
follow the pattern given in Whitehead et al. (2006a).  For the DLE data, a Tsutukawa 
(1975) prior density h0(λ1, λ2) is used for λ1 and λ2, defined by  
( ) ( ){ } ( ){ }




1 2 1 1 2 0
0 1 2 w w
1 2 1 1 2 0
exp y exp y
h ,





λ +λ λ + λ
λ λ ∝
+ λ + λ + λ +λ
, 
where the parameters vk and wk reflect opinion about the risk of a DLE when 
log(AUC+1) = yk, k = −1, 0.  This prior, and the corresponding posterior, is discussed 
by Whitehead and Williamson (1998). 
The Bayesian decision procedure concerns the choice of dose to be administered 
to the i
th
 subject in the j
th
 treatment period.  The pattern of administering placebo doses 
used in the real study is preserved in the new design.  Thus, for the first cohort patients 
1, 2 and 3 (randomly selected) receive placebo during the first treatment period, patients 
4, 5 and 6 when they return for the third treatment period and patients 7, 8 and 9 during 
the fifth period.  A similar system operates for the second cohort during treatment 
periods 2, 4 and 6.  The Bayesian procedure is used to choose which active doses to 
administer to those due to receive them.  By the j
th
 treatment period, posterior models 
will have been developed from the data collected during the first (j − 1) treatment 
periods.  First, safety constraints will be set to avoid doses likely to lead to an excess 
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plasma concentration or a high risk of a DLE.   Only doses for which the probability 
that (yij ≥ L) is less than 0.05 should be administered, and only doses for which the 
probability of a DLE is less than 0.2.  The former probabilities are found from the 
predictive t-distribution of yij, which is described by Whitehead et al. (2006a), and 
estimated before each dosing period by replacing the unknown coefficients by their 
current posterior modal estimates.  A posterior distribution is available for the subject 
effects relating to those who have previously been observed: for new subjects, the prior 
subject effect distribution is used.  For the probability of a DLE to be less than 0.2, it is 
necessary that λ1 + λ2yij < logit(0.2) = −1.3863.  A simple approach would be to replace 
λ1 and λ2 by their posterior modal estimates, and yij by its expected value based on the 
dose dij administered and the posterior modal estimates of β and si, and determine 






1 2 1 2
1 2 1 2
exp y exp y
P(DLE ) E g(y)dy
1 exp y 1 exp y
 λ + λ λ + λ = = + λ + λ + λ + λ  
∫λ ,                   
where g is the predictive t-density of y.  Only doses for which this integral is less than 
0.2 can be used.  Once more λ1 and λ2 are replaced by their posterior modal estimates, 
but now variation in y and some of the dependency between the DLE risks of the same 
individual in different dosing periods is allowed for.  
The set of available doses that satisfy the two safety constraints can be found for 
each subject in the next dosing period.  These sets might differ from patient to patient 
according to current knowledge of their individual subject effect.  The final 
recommendation from the subset of permissible available doses is determined according 
to the predictive distribution of the pulse rate.  A desirable range of values (ML, MU) 
will be defined, ML denoting the minimal maximum increase consistent with a 
beneficial effect and MU the maximum safe increase.  Ideally, the dose that maximises 
the probability that mij ∈ (ML, MU) should be chosen.  Here, we adopt the simpler but 
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more tractable criterion of choosing the dose that makes E(mij) closest to ½(ML + MU) 
amongst those in the available list of doses that satisfy the two safety constraints.  The 
method for computing E(mij) is described in the Appendix.   
 
4. An illustration of the procedure 
The settings chosen for this illustration were motivated by the real data collected in the 
completed trial.  In practice, discussions with clinical investigators and consideration of 
data from previous, similar studies would be used to make these choices.  The limiting 
value for log(AUC + 1) is to L = 9.7, corresponding to an AUC of approximately 16000 
µg h mL−1.  The limits for maximum increase in pulse rate are set at ML = 10 bpm and 
MU = 45 bpm.   
Fixed values for within subject correlations of the yij and the mij are taken as ρ = 
0.6 and η = 0.3 will be imposed.  Prior information concerning AUC values is 
expressed as two representative pseudo-observations on a single subject: AUC values of 
550 and 6900 corresponding to doses 40 mg and 180 mg respectively are specified. 
These lead to a slope of a 1.7, consistently with the observed data.  For the DLE model, 
following and Zhou and Whitehead (2003) prior opinion is expressed by supposing that 
3 “pseudo-subjects” at dose 20 gave 0.6 of a DLE and 3 at dose 200 gave 1.5 DLEs.  
This leads to prior modal parameter estimates of λ1 = −3.255 and λ2 = 0.361. 
Prior information on pulse rates is represented by three representative pseudo-
observations on a single subject.  These were maximum increases over baseline of 21, 
25 and 50 bpm corresponding to AUC values of 0, 1000 and 22,000 respectively.  The 
resulting prior modal parameter estimates are θ1 = 21, θ2 = −4.611 and θ3 = 0.751.  This 
prior model predicts pulse rate values corresponding to doses in the region of 20mg to 
be similar to those expected under placebo.   
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To choose the gamma parameters for AUC, aA0 and bA0, it was required that the 
lowest dose have a prior probability of an excessive AUC value equal to 0.05, while for 
the second dose this probability is 0.067 (see Whitehead et al.; 2001).  This choice 
ensures that the only permissible dose for the first cohort will be the lowest dose. The 
parameter values aA0 = 0.42529 and bA0 = 0.0355 follow.  It was not necessary to 
specify the gamma parameters for the prior distribution of  ξ−2, as the dose escalation 
procedure depends only on expectations of the mij.  The data used in the following 
simulation examples were generated using the models described above, with AUC 
parameters set at β = 1.709, σ2 = 181.79 and τ2 = 15.631, pulse rate parameters set at 
θ0 = 21.5, θ1 = −2.17, θ2 = 0.36, ξ2 = 0.0554 and ζ2 = 0.340 and DLE parameters set at 
λ1 = −4.048, and λ2 = 0.347.   
 Each simulated run involved two cohorts of 9 healthy male volunteers and six 
dosing periods.  Cohort I participated in periods 1, 3 and 5 and Cohort II in periods 2, 4 
and 6.  During each dosing period, three subjects received placebo, arranged so that 
each subject received placebo exactly once.  The doses available were 0, 20, 40, 80, 
120, 180 and 200 mg.  Thus, the simulated studies resembled the real one, except that 
doses were chosen according to the recommendations of the Bayesian procedure.  To 
enhance comparability of different design options, the investigation began with 
simulation of two subject responses to each of the available doses.  Then in each run, 
subject responses were read from this complete dataset.  This ensures that when two 
procedures coincide in dose allocation, the results of the simulated runs will be the 
same.   
Before studying data from the simulated trials, the real data described in Section 
2 will be revisited.  Figure 3 summarises the responses to each active dose.  Dose 
administered is plotted against dosing period.  The symbol is heart-shaped if the 
maximum increase in pulse rate over baseline lies in the target interval (10, 45) bpm, 
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square if it lies below 10 and triangular if it lies above 45.  The symbol is printed larger 
if the log(AUC + 1) value exceeded the limit of 9.7, (this occurs only in the actual 
dataset shown in Figure 3), and it is filled if a DLE was observed.  The figure shows 
that DLEs were quite common, even at the lowest dose, and thus cannot have been 
considered to be a particularly vital limitation to escalation.  At the highest dose, the 
AUC limit was exceeded twice.  Suitable pulse rate increases were observed at all dose 
levels, including the lowest, indicating that raising the dose was not critical for the 
achievement of a potentially pharmacological effect.  
FIGURE 3 NEAR HERE 
Figure 4 shows the results from a simulated dose-escalation study, depicted in 
the same way as Figure 3.  The data illustrate some important operating characteristics 
of the methodology.   Excess AUC values are avoided completely.  As satisfactory 
pulse rates are found from low doses, the higher range is not entered.  Fewer DLEs are 
observed.  One subject is given dose 80 during the last period: this subject exhibited 
individual effects indicating that a higher dose would be both safe and effective.  Thus 
the procedure can tailor dosing to the individual subject.  
FIGURE 4 NEAR HERE 
The escalation shown in Figure 4 is conservative, with only one subject 
advancing beyond dose 40.  Detailed scrutiny of the data suggests that this is because of 
the fear of DLEs.  In the actual study, DLEs were observed, and yet escalation 
continued.  This suggests that we need not be too concerned about their occurrence. 
Consequently, in the next run of the procedure, the tolerance relating to DLEs was 
altered to ensure that the risk was less that 0.3 rather than the stricter setting of 0.2.  The 
result is shown in Figure 5.  Doses up to 80mg are now administered to many subjects, 
and dose 120 appears twice.  There are still no excessive AUC values, and a high 
proportion of the subjects have pulse rate increases in the target range.  
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FIGURE 5 NEAR HERE 
 Finally, a third refinement of the dose selection procedure was 
investigated.  As subjects become used to taking the drug, and once it is established that 
no harmful rises in heart rate are experienced, the target values for the pulse rate 
measure can be progressively increased.  Thus, for dosing periods 1, 2 and 3, ML will 
set at 10, but it will be raised to 20 for periods 4 and 5 and finally to 30 for period 6.   
Within this scheme placebo subjects in Cohort II will start with ML = 20, but the 
experience of Cohort I subjects dosed using the stricter criterion should provide 
sufficient assurance to allow this.  Figure 6 shows the results from a simulated run using 
these criteria, and with the DLE tolerance set at 0.30.  Now the top dose of 200 is 
reached, but still no excess AUC values are encountered.  Most administrations result in 
an acceptable pulse rate.  In this plot, the symbol is heart-shaped if the maximum 
increase in pulse rate over baseline lies in the current target interval, with lower limit 
10, 20 or 30 according to dosing period: squares denote values that are too low and 
triangles values that are too high.    
FIGURE 6 NEAR HERE 
During all three simulation runs, very few dose allocations were constrained by 
the need to keep the AUC below its limiting value.  This would occur in practice if the 
physiological target was reached well within the acceptable limit of plasma 
concentration.  In conventional studies, there is often a desire to learn about the 
maximum tolerated dose of a drug.  If therapeutic value can be found well within the 
tolerable range, knowledge of the maximum may not be pharmacologically important.  
It certainly may not be needed prior to the proof-of-concept studies that may lead to 
more extensive clinical development.  Escalating to find the maximum tolerated dose is 
potentially one of the most hazardous parts of healthy volunteer testing, although it may 
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eventually be needed to determine the properties of or adverse reactions to the drug if 
overdosing occurs once the drug becomes widely available. 
Table 1 presents maximum likelihood estimates from all three simulated runs.  
Maximum likelihood is used to avoid the influence of the prior information in this final 
analysis.  The estimates from the run shown in Figure 6 are the most accurate and have 
the smallest standard errors, which follows because this run involved the widest range 
of doses.  In the other runs, σ2 is overestimated and τ2 is underestimated, consistently 
with the findings of Whitehead et al. (2006a).  In all runs ξ2 is substantially 
underestimated.  Table 1 also presents the maximum safe doses d*AUC and d*DLE under 
the AUC and DLE criteria, and the ideal dose d*pulse for achieving the target dose.  
These are underestimated in the runs shown in Figures 4 and 5 and overestimated in that 
shown in Figure 6.  
 
TABLE 1 NEAR HERE 
All runs were completed using the predictive probability P(DLE λ) described in 
Section 3.  Earlier runs using the simpler approach in which yij is replaced by its 
expected value based on the dose dij administered gave the same dosing pattern.  The 
exact values of the maximum safe doses d*AUC and d*DLE under the AUC and DLE 
criteria, and the ideal dose d*pulse for achieving the target dose were different, but the 
closest suitable doses amongst those available were unchanged.   
 
5. Discussion 
This paper addresses issues of dose escalation in early phase studies in which a 
pharmacodynamic response that is predictive of the mechanism of action of the drug 
follows closely after administration of the drug and is quickly available.  The rationale 
for anticipating that moderate elevation of pulse rate will indicate therapeutic value in 
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ADHD has been explained in Section 1.  In other settings, different pharmacodynamic 
endpoints might be used.  Whitehead et al. (2006b) discuss examples including the 
observation of anti-factor Xa activity as being indicative of thromboembolic disorders 
or inhibition of leukotriene B4 being indicative of anti-inflammatory activity.  In the 
current application, a quadratic model was used for the relationship between 
transformed versions of the pharmacodynamic and pharmacokinetic responses.  This 
could be applied as a conservative alternative to a break point model or to the lower part 
of an Emax model: conservative in the sense that higher doses will appear more 
dangerous under the quadratic model and will thus be avoided until sufficient evidence 
of their safety has been collected.  The authors recognise that each clinical study is 
unique, and that the details of other trials may be different from that studied here.  
Rather than presenting our method as a “one size fits all” approach, we hope that the 
considerations made in developing this design will serve as a useful model even when 
study details are different.   
The objective of the methodology described is the identification of the dose that 
is most likely to have therapeutic value.  More conventional approaches seek the 
maximum tolerated dose, but the importance and ethics of raising doses until harm is 
observed are doubtful if such activity occurs only well above the therapeutic range.  
Certainly, such questions become of interest only when the proof-of-concept stage has 
been passed, and it is clear that the drug has potential for widespread use.  If necessary, 
the effects of higher doses can be addressed if and when that later stage has been 
reached.  
The prior information for the approach will generally be derived from animal 
experimentation and from prior human experience with similar compound. The benefits 
of the methodology will depend on the extent and reliability of this prior information. 
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Sometimes there will be delays in processing pharmacokinetic data, so that  
observed AUC values are not available immediately after dosing.  The Bayesian model 
can be updated using whatever data are available, and so can continue to be informative 
despite missing data.  Nevertheless, every effort should be made to assemble most, if 
not all, of the necessary data in a timely fashion.  Zhou et al. (2007) describe how this 
was successfully achieved in their study. 
Some details of the scheme described could easily be varied.  Summary 
measures for pulse rate other than the maximum could be used.  For example, the 
weighted mean pulse rate (taken to be the area under the pulse rate-time curve) would 
penalise doses leading to a high pulse rate maintained over several hours, which might 
be of more concern than the occurrence of an isolated maximum value.  Doses for the 
motivating study could have been made up from any combination of the available 
capsule sizes (10, 50 and 100 mg), and so more dose levels could have been created, 
and higher doses could have been made available.  The dose-escalation scheme 
described in this paper does not require all available doses to be tried in turn, and so it 
can be used with a larger set of potential doses without extending its duration.  The 
procedure homes in on the interesting doses, and it is advantageous to provide a finer 
grid of dose values than is conventionally done in order to identify the optimal choice 
more accurately.    
The methodology described in this paper provides a framework from which the 
safety and pharmacodynamic effects of different doses can be foreseen, together with an 
expression of the reliability of such predictions.  The method provides a formal 
recommendation of the doses to be used during the next dosing period, but a safety 
committee will usually weigh these against other information not captured by the formal 
scheme, and decide whether or not to accept the recommendation.  The modelling 
provides more information than the final recommendation of doses, and this can be used 
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to help with decision making.  In applying a similar dose-escalation scheme, Zhou et al. 
(2007) report that over 70% of formal dosing recommendations were accepted for 
administration, and that the fitted models were helpful in reaching the remaining dosing 
decisions.     
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Appendix: Derivation of the expected value of mij  
 
According to the model of Section 2, 2 2ij 1 0 1 ij 2 ij im | R ~ N( y y r , )θ + θ + θ + ξ  and 
2
ij 2 ij iy | R ~ N( s , )β + σl , where R1 = 
2 2
ij i i{y , r ,s , , , , }θ β ξ σ  and  R2 = 
2 2
i i{r ,s , , , , }.θ β ξ σ  
It follows that ij 1E(m | R ) =
2
0 1 ij 1 ij iy y rθ + θ + θ + .  We will now take expectations over 
each of the conditioning variables in turn, in order to “unpeel” the expectation of mij.  
Taking expectations over yij, remembering that E(X
2
) = var(X) + {E(X)}
2
, we obtain 
 ( ) ( ) ( )2 2 2 2ij 2 0 1 ij i 2 ij i ij i iE m | R s 2s s r= θ + θ β + + θ σ +β + β + +l l l . 
Now, in a manner similar to the derivation of equation (3.5) in Whitehead et al. (2001), 
it can be shown that the posterior distribution of ri, given θ, ξ2 and η is normal, with 
mean ( ){ }2(1)i i 0 1 i 2 iw m y y−θ − θ − θ and variance 2 (1)i iw / nξ , and that the posterior 
distribution of si, given θ, σ2 and ρ is normal, with mean { }(2)i i iw y −β l and variance 
2
(1)i iw / nσ , where (1)iw =  ( ){ }i in / 1 n 1η + − η , (2)iw =  ( ){ }i in / 1 n 1ρ + − ρ , ni is the 
number of active doses that subject i has received and ( )2i i i im , , y and yl are the means 
of the mij, lij, yij and 
2
ijy  values recorded for this subject.  Taking expectations over ri 
and si, we obtain 
 
( ) ( ) { }
{ } { } { } ( )
ij 3 (1)i i 0 (1)i 1 ij (2)i i (1)i (2)i i
2
2 2 2 2
2 (1)i i ij (2)i i i ij i i (1)i i
E m | R w m 1 w w w w y
1 w / n 2w y y w y
 = + θ − + θ β − β − − 
 + θ σ + +β + −β β + −β −  
l l
l l l l
 
where R3 = 
2 2{ , , , }.θ β ξ σ   Finally, taking expectations with respect to θ and β, we 
obtain E(mij) as the expression above with θ0, θ1, θ2, and β replaced by their Bayes 
estimates and β2 replaced by the sum of its variance and the square of its estimate. 
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Captions for figures 
 
 
Figure 1:  Scatter plot of log(AUC+1) data, with the fitted model superimposed. Dotted 
lines are the 95% confidence limits for the response of a new subject 
 
Figure 2:  Scatter plot of the pulse rate data against transformed AUC, with the fitted 
curve superimposed 
 
Figure 3:  Plot of the observed study data 
Figure 4:  A simulated dose-escalation study with a DLE tolerance of 0.2 
Figure 5:  A simulated dose-escalation study with a DLE tolerance of 0.3 
Figure 6:  A simulated dose-escalation study with a DLE tolerance of 0.3 and a 




























































Table 1:  Maximum likelihood estimates of parameters following the three simulated 
runs 
Parameter Truth Figure 4 Figure 5 Figure 6 






σ2 0.055 0.055 0.079 0.068 
τ2 0.340 0.311 0.264 0.253 


















ξ2 182 106 103 94 
ζ2 15.6 7.9 10.0 21.2 












d*AUC 158 150 156 162 
d*DLE 90 64 76 151 
d*pulse 104 73 83 124 
 
